Filing Flows › Phathom Pharmaceuticals (PHAT) › Guidance history
Phathom Pharmaceuticals (PHAT) guidance history: what it guided and what it reported
Phathom Pharmaceuticals gave guidance in 3 earnings releases on file since Apr 30, 2026.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $320M–$345M (Apr 30, 2026) → lowered $310M–$325M (Jul 30, 2026) → reaffirmed $310M–$325M (Oct 29, 2026) | — | to be reported | — |
Gross margin
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 80.0% (Apr 30, 2026) → reaffirmed 80.0% (Jul 30, 2026) → reaffirmed 80.0% (Oct 29, 2026) | — | to be reported | — |
The latest quarter
Phathom Pharmaceuticals, Q3 2026: revenue $84.7M (+71% year over year), operating margin -0.1%, net loss $13.9M, operating cash flow $1.8M. The chart follows the revenue to costs, profit and cash.
Questions
Does Phathom Pharmaceuticals beat its guidance?
Phathom Pharmaceuticals gave guidance in 3 earnings releases on file since Apr 30, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.